Imitochondrial antibodies

Pietro Invernizzi, Carlo Selmi, M. Eric Gershwin

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Serum antimitochondrial autoantibodies (AMA) are the diagnostic hallmark of primary biliary cirrhosis (PBC), being detected in 90-95% of affected individuals. AMA autoantigens have been mapped within three structurally and functionally related multienzymic complexes located on the inner mitochondrial membrane, that is, the 2-oxoacid dehydrogenase complexes. More specifically, AMA most commonly are directed against lipoylated domains within the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2). It is to note that AMA may appear years before the onset of PBC. Despite their high specificity for PBC, proof of a direct or indirect pathogenic role for AMA is still awaited. Moreover, AMA titers or specificity do not correlate or predict the clinical course of the disease. Novel methods for the detection of serum AMA are being developed that are increasing the sensitivity of the test. In the clinical environment, the routine method for serum AMA detection is indirect immunofluorescent that produces a typical pattern above, a titer higher than 1:40 is considered as positive. More recently, recombinant mitochondrial antigens have been made available. The use of these antigens, either by immunoblotting or enzyme-linked immunosorbent assay (ELISA), have significantly increased the sensitivity and specificity of the test. These tests, however, are currently available only for research purposes in selected laboratories.

Original languageEnglish
Title of host publicationAutoantibodies
PublisherElsevier Inc.
Pages473-477
Number of pages5
ISBN (Print)9780444527639
DOIs
Publication statusPublished - 2007

Fingerprint

Autoantibodies
Antibodies
Biliary Liver Cirrhosis
Dihydrolipoyllysine-Residue Acetyltransferase
Serum
Pyruvate Dehydrogenase Complex
Keto Acids
Antigens
Immunosorbents
Autoantigens
Mitochondrial Membranes
Immunoblotting
Assays
Oxidoreductases
Enzyme-Linked Immunosorbent Assay
Membranes
Sensitivity and Specificity
Enzymes
Research

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Invernizzi, P., Selmi, C., & Eric Gershwin, M. (2007). Imitochondrial antibodies. In Autoantibodies (pp. 473-477). Elsevier Inc.. https://doi.org/10.1016/B978-044452763-9/50063-9

Imitochondrial antibodies. / Invernizzi, Pietro; Selmi, Carlo; Eric Gershwin, M.

Autoantibodies. Elsevier Inc., 2007. p. 473-477.

Research output: Chapter in Book/Report/Conference proceedingChapter

Invernizzi, P, Selmi, C & Eric Gershwin, M 2007, Imitochondrial antibodies. in Autoantibodies. Elsevier Inc., pp. 473-477. https://doi.org/10.1016/B978-044452763-9/50063-9
Invernizzi P, Selmi C, Eric Gershwin M. Imitochondrial antibodies. In Autoantibodies. Elsevier Inc. 2007. p. 473-477 https://doi.org/10.1016/B978-044452763-9/50063-9
Invernizzi, Pietro ; Selmi, Carlo ; Eric Gershwin, M. / Imitochondrial antibodies. Autoantibodies. Elsevier Inc., 2007. pp. 473-477
@inbook{8dacf7a996b344a6996f6c8f4d0aeee4,
title = "Imitochondrial antibodies",
abstract = "Serum antimitochondrial autoantibodies (AMA) are the diagnostic hallmark of primary biliary cirrhosis (PBC), being detected in 90-95{\%} of affected individuals. AMA autoantigens have been mapped within three structurally and functionally related multienzymic complexes located on the inner mitochondrial membrane, that is, the 2-oxoacid dehydrogenase complexes. More specifically, AMA most commonly are directed against lipoylated domains within the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2). It is to note that AMA may appear years before the onset of PBC. Despite their high specificity for PBC, proof of a direct or indirect pathogenic role for AMA is still awaited. Moreover, AMA titers or specificity do not correlate or predict the clinical course of the disease. Novel methods for the detection of serum AMA are being developed that are increasing the sensitivity of the test. In the clinical environment, the routine method for serum AMA detection is indirect immunofluorescent that produces a typical pattern above, a titer higher than 1:40 is considered as positive. More recently, recombinant mitochondrial antigens have been made available. The use of these antigens, either by immunoblotting or enzyme-linked immunosorbent assay (ELISA), have significantly increased the sensitivity and specificity of the test. These tests, however, are currently available only for research purposes in selected laboratories.",
author = "Pietro Invernizzi and Carlo Selmi and {Eric Gershwin}, M.",
year = "2007",
doi = "10.1016/B978-044452763-9/50063-9",
language = "English",
isbn = "9780444527639",
pages = "473--477",
booktitle = "Autoantibodies",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Imitochondrial antibodies

AU - Invernizzi, Pietro

AU - Selmi, Carlo

AU - Eric Gershwin, M.

PY - 2007

Y1 - 2007

N2 - Serum antimitochondrial autoantibodies (AMA) are the diagnostic hallmark of primary biliary cirrhosis (PBC), being detected in 90-95% of affected individuals. AMA autoantigens have been mapped within three structurally and functionally related multienzymic complexes located on the inner mitochondrial membrane, that is, the 2-oxoacid dehydrogenase complexes. More specifically, AMA most commonly are directed against lipoylated domains within the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2). It is to note that AMA may appear years before the onset of PBC. Despite their high specificity for PBC, proof of a direct or indirect pathogenic role for AMA is still awaited. Moreover, AMA titers or specificity do not correlate or predict the clinical course of the disease. Novel methods for the detection of serum AMA are being developed that are increasing the sensitivity of the test. In the clinical environment, the routine method for serum AMA detection is indirect immunofluorescent that produces a typical pattern above, a titer higher than 1:40 is considered as positive. More recently, recombinant mitochondrial antigens have been made available. The use of these antigens, either by immunoblotting or enzyme-linked immunosorbent assay (ELISA), have significantly increased the sensitivity and specificity of the test. These tests, however, are currently available only for research purposes in selected laboratories.

AB - Serum antimitochondrial autoantibodies (AMA) are the diagnostic hallmark of primary biliary cirrhosis (PBC), being detected in 90-95% of affected individuals. AMA autoantigens have been mapped within three structurally and functionally related multienzymic complexes located on the inner mitochondrial membrane, that is, the 2-oxoacid dehydrogenase complexes. More specifically, AMA most commonly are directed against lipoylated domains within the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2). It is to note that AMA may appear years before the onset of PBC. Despite their high specificity for PBC, proof of a direct or indirect pathogenic role for AMA is still awaited. Moreover, AMA titers or specificity do not correlate or predict the clinical course of the disease. Novel methods for the detection of serum AMA are being developed that are increasing the sensitivity of the test. In the clinical environment, the routine method for serum AMA detection is indirect immunofluorescent that produces a typical pattern above, a titer higher than 1:40 is considered as positive. More recently, recombinant mitochondrial antigens have been made available. The use of these antigens, either by immunoblotting or enzyme-linked immunosorbent assay (ELISA), have significantly increased the sensitivity and specificity of the test. These tests, however, are currently available only for research purposes in selected laboratories.

UR - http://www.scopus.com/inward/record.url?scp=34948831900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34948831900&partnerID=8YFLogxK

U2 - 10.1016/B978-044452763-9/50063-9

DO - 10.1016/B978-044452763-9/50063-9

M3 - Chapter

AN - SCOPUS:34948831900

SN - 9780444527639

SP - 473

EP - 477

BT - Autoantibodies

PB - Elsevier Inc.

ER -